Ceftazidime: Nursing Drug Guide, Renal Dosing & Pseudomonas Coverage
Antipseudomonal third-generation cephalosporin for serious gram-negative infections—but when GFR falls below 50 mL/min without dose adjustment, elevated serum levels can trigger seizures, encephalopathy, and myoclonia. Verify renal function before every course, never mix with aminoglycosides in the same bag, and stop at the first neuro or CDAD red flag.
Ceftazidime can cause life-threatening neurotoxicity—seizures, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia—especially when glomerular filtration rate is less than 50 mL/min and the dose or interval is not adjusted. Elevated serum levels in renal insufficiency have caused these reactions in patients given unadjusted regimens, including older adults. Before the first dose and after any change in renal function, verify pharmacy-adjusted orders against current GFR/CrCl. If new neurologic symptoms appear, hold ceftazidime, notify the prescriber, and institute supportive care; hemodialysis or peritoneal dialysis may aid removal in renal failure per labeling.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Recalculate GFR/CrCl before every ceftazidime course and after acute kidney injury, dehydration, or diuretic changes—then confirm the MAR matches Table 4 when GFR is below 50 mL/min. New myoclonus or altered mental status in a patient on ceftazidime is a hold-and-escalate event until neurotoxicity and supratherapeutic exposure are ruled out.
Most common brand names
Ceftazidime is available generically and as Tazicef and Fortaz. Vials contain ceftazidime pentahydrate with sodium carbonate to aid dissolution (≈54 mg sodium per g of drug activity). Strengths are typically 1 g and 2 g—verify vial label, reconstitution volume, and renal-adjusted interval on the MAR, not just the antibiotic name.
Why we give it — Indications
Ceftazidime is a third-generation antipseudomonal cephalosporin for serious gram-negative infections—including many Pseudomonas aeruginosa strains—when IV or IM therapy is ordered. It may be used alone for confirmed or suspected sepsis or combined with aminoglycosides, vancomycin, or clindamycin for severe infections per prescriber and pharmacy guidance. Nurses most often see it for hospital-acquired or complicated infections after cultures are sent.
| Use | Detail |
|---|---|
| Pneumonia | Mild pneumonia and skin infections (500 mg–1 g IV/IM q8h); serious intra-abdominal, gynecologic, or meningitis regimens use 2 g IV q8h per Table 3 |
| Urinary tract infection | Uncomplicated urinary tract infection (250 mg q12h); complicated UTI (500 mg q8–12h) per labeling |
| Pseudomonas respiratory infection | 2 g IV q8h for very severe infections; cystic fibrosis regimens use 30–50 mg/kg IV q8h (max 6 g/day) when renal function is normal |
| Empiric / febrile neutropenia | Gram-negative coverage while awaiting blood cultures—often with other agents per protocol |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Ceftazidime inhibits bacterial cell-wall synthesis (beta-lactam) with strong antipseudomonal activity among third-generation cephalosporins. Approximately 80–90% of an IV or IM dose is excreted unchanged in urine within 24 hours; when GFR falls below 50 mL/min, serum levels rise and neurotoxicity risk increases unless dose and interval are reduced per Table 4.
Dosing overview
Standard adult regimens apply when GFR is 50 mL/min or greater. When GFR is less than 50 mL/min, adjust dose and/or interval per Table 4 in Hospira labeling—this is the primary nursing safety checkpoint for neurotoxicity prevention.
Table 4 (Tazicef label) maintenance when GFR is less than 50 mL/min — if the Table 3 dose is lower than the Table 4 row, use the lower dose per labeling.
| Creatinine clearance | Example shifts (consult full Table 4 for all dose ladders) |
|---|---|
| ≥ 50 mL/min | Standard Table 3 schedule (e.g., 1 g q8–12 h; 2 g q8 h for severe/Pseudomonas infections). |
| 50–31 | 1 g every 12 hours. |
| 30–16 | 1 g every 24 hours. |
| 15–6 | 500 mg every 24 hours. |
| < 5 | 500 mg every 48 hours. |
| CAPD | Loading 1 g, then 500 mg every 24 hours; may add 250 mg per 2 L dialysis fluid per labeling. |
| Hemodialysis | Loading 1 g, then 1 g after each hemodialysis session. |
On a small screen, swipe or scroll sideways to see the full table.
Estimate CrCl when only serum creatinine is available (Cockcroft-Gault per labeling). Trend eGFR and creatinine during diuretic therapy, contrast, or sepsis-related acute kidney injury.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact pharmacy for the next safe administration time when renal function is borderline.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Administration | IV push 3–5 min or IV infusion in compatible fluid | Never give intra-arterially; avoid bolus if infusion ordered |
| Half-life (healthy adults) | ≈1.9 hours IV (mean) | Prolonged when GFR <50—extend interval per Table 4 |
| Elimination | ≈80–90% unchanged in urine | Renal dose reduction mandatory when GFR <50 mL/min |
| Hemodialysis | Drug removed during session | 1 g load, then 1 g after each HD per Table 4 |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm beta-lactam allergy history (penicillin, cephalosporin, carbapenem) and prior immediate hypersensitivity
- Calculate or verify CrCl/eGFR; compare MAR dose and interval to renal adjustment table—especially in chronic kidney disease or rising creatinine
- Perform medication reconciliation for concurrent nephrotoxins or IV incompatibilities
Contraindications
- Hypersensitivity to ceftazidime or the cephalosporin class of antibacterial drugs
- Intra-arterial administration must be avoided—distal necrosis can occur after inadvertent intra-arterial injection
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Furosemide / dehydration | Volume depletion and AKI raise ceftazidime levels and neurotoxicity risk | Monitor I&O, creatinine, mental status; request dose re-evaluation if renal function worsens |
| Aminoglycosides | Nephrotoxicity reported with cephalosporins plus aminoglycosides or potent diuretics such as furosemide | Monitor renal function during prolonged combined therapy; do not add ceftazidime and aminoglycosides to the same solution—administer separately |
| Probenecid | May increase ceftazidime exposure | Notify pharmacist if probenecid is added during ceftazidime therapy |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Intravenous or intramuscular. For direct IV, inject slowly over 3 to 5 minutes or infuse in compatible fluid per FDA labeling. Avoid intra-arterial injection.
- Reconstitute vials per labeling—vials are under reduced pressure; follow constitution instructions to avoid spray-back
- Inspect for particulates and leaks before administration; follow IV infusion pump setup when infusing
- Do not add ceftazidime to the same solution as aminoglycosides. Vancomycin shows physical incompatibility—flush the line and administer separately when both are ordered
- Use high-alert medication administration practices when verifying mg, diluent volume, rate, and renal-adjusted schedule
Expected therapeutic response
- Defervescence and improving clinical status for the treated infection (when paired with source control and culture-directed therapy)
- Down-trending inflammatory markers and culture clearance when susceptibilities confirm ceftazidime activity
- Stable neurologic baseline—ceftazidime should not cause new confusion or myoclonus when appropriately dosed
Red flags — Stop and act
Hold ceftazidime and escalate immediately for neurologic toxicity, severe hypersensitivity, or fulminant CDAD.
- New altered mental status, seizures, encephalopathy, asterixis, neuromuscular excitability, or myoclonia—especially with renal impairment or unadjusted dosing
- Urticaria, bronchospasm, hypotension, or other signs of anaphylaxis during or after infusion
- Generalized rash, mucosal lesions, or blistering (possible severe cutaneous reaction)
- Profuse watery diarrhea with abdominal pain or fever during or after antibiotic therapy (evaluate for antibiotic-associated diarrhea / CDAD)
- Creatinine rise, oliguria, or missed renal dose adjustment on the MAR when neuro symptoms appear
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Rash, pruritus | Common at higher doses (≥1%) | Monitor progression; discontinue if serious skin reaction suspected |
| Diarrhea, nausea, vomiting | Common (≥1% at 2 g q8h) | Assess hydration; evaluate for CDAD if profuse or bloody |
| Neurotoxicity | Serious; often with renal impairment | Hold drug, notify prescriber, supportive care, consider hemodialysis per labeling |
| Positive Coombs test | Laboratory finding | Document; correlate with hemolysis symptoms if present |
| Increased AST/ALT, PT/PTT | Reported in trials | Trend hepatic panel and coagulation studies per protocol |
| Local infusion reactions | Phlebitis, pain at site | Assess IV site; rotate per policy; report persistent inflammation |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
No specific antidote is listed in Hospira ceftazidime labeling. Overdose symptoms mirror neurotoxicity: encephalopathy, myoclonus, seizures, and neuromuscular excitability. Accidental overdosing has occurred when large doses were given to patients with impaired renal function.
Management
- Discontinue ceftazidime and provide supportive care with close neurologic monitoring
- In renal insufficiency, hemodialysis or peritoneal dialysis may aid removal
- Contact prescriber, pharmacist, and local poison control / toxicology services per facility protocol
Look-alike / sound-alike and error prevention
- Ceftazidime vs cefepime vs ceftriaxone—third-gen antipseudomonal vs fourth-gen vs long-acting cephalosporins with different renal thresholds
- Ceftazidime vs ceftazidime/avibactam (Avycaz)—verify generic name; avibactam combination extends beta-lactamase coverage
- 1 g q8h vs 1 g q24h—Table 4 renal edits look minor on the MAR but sharply change drug exposure
- 2 g vial reconstituted in 10 mL—confirm full ordered dose is prepared; partial doses require pharmacy
- Vancomycin Y-site with ceftazidime—precipitation risk; run sequentially with line flush per pharmacy
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Renal recheck triggers | New diuretics, contrast, hypotension, rising creatinine—request pharmacy re-evaluation before next dose |
| Neuro checks | Baseline and daily mental status in older adults and CKD; myoclonus or word-finding trouble = stop and escalate |
| Infusion time | 3–5 minutes (direct IV) or compatible infusion; reprogram pump if rate error discovered mid-infusion |
| Frozen bags | Room-temp thaw; gentle swirl; discard if cloudiness or precipitate persists |
| Commonly missed | Standard q8h order left unchanged after AKI; home dialysis schedule not communicated to pharmacy |
| Ask pharmacy when | GFR <50, HD/CAPD patient, suspected neurotoxicity, or incompatible IV meds on same line |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Higher baseline renal impairment; labeling reports serious neurotoxicity in geriatric patients given unadjusted doses |
| Renal impairment / dialysis | Mandatory Table 4 adjustment at GFR <50; HD dosing timed after dialysis session |
| Penicillin allergy history | Cross-reactivity up to 10%; obtain allergy clarification before first dose |
| Critical illness with fluctuating CrCl | Sepsis, shock, and diuretics alter renal function daily—do not assume admission CrCl still applies |
| Pregnancy | Pregnancy Category B—animal studies showed no fetal harm at up to 40× human dose; no adequate controlled studies in pregnant women. Use during pregnancy only if clearly needed per labeling. |
| Lactation | Excreted in human milk in low concentrations; use caution in nursing mothers per labeling. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Renal function (creatinine, basic metabolic panel) at baseline and during therapy when CrCl may change
- Neurologic status (orientation, speech, myoclonus, seizure activity) at least each shift—more often if renal impairment
- Infection markers (temperature, WBC, culture results) and stool pattern for CDAD
- IV site and infusion completion times
Document
- CrCl/eGFR used to verify dose, actual dose infused, rate, and time
- Any held doses with prescriber/pharmacist notification and neuro symptom timeline
- Patient teaching on reporting diarrhea, rash, or confusion
Patient teaching
- Report sudden confusion, twitching, trouble speaking, or seizures immediately—even if the infection seems to be improving
- Report severe or persistent diarrhea, especially if bloody or accompanied by abdominal pain
- Report rash, itching, swelling, or trouble breathing during infusion
- IV antibiotics require full infusion time; notify the nurse if the pump alarms or the site burns
The Hold Rule
- Any new neurotoxicity sign (confusion, myoclonus, seizure, coma and asterixis)
- GFR <50 with an order that does not match renal adjustment table
- Known or suspected beta-lactam anaphylaxis or serious cutaneous reaction
- Profuse CDAD-type diarrhea pending evaluation
- Pump rate error delivering dose faster than labeled IV push or infusion without prescriber guidance
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Ceftazidime is often ordered on sepsis pathways where renal function changes hourly. Build CrCl verification into antibiotic time-outs alongside culture review—neurotoxicity is preventable when dose and interval match kidney function.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right renal-adjusted interval
- Compare today’s creatinine/CrCl to the value used when the order was written
- Independent double-check bag strength (1 g vs 2 g vial strength) and pump duration (3–5 min or infusion)
- Confirm incompatible agents will be administered separately
2. High-alert and safety badge
Renal neurotoxicity risk — treat dose/interval verification as high-stakes even when not on institutional high-alert listHospira labeling warns that unadjusted dosing in renal impairment has caused fatal encephalopathy and seizures. Use the same rigor as high-alert IV antibiotics when CrCl is ≤60.
3. Clinical workflow: hold and question rules
- If neuro symptoms appear, hold the next dose and page prescriber/pharmacy before restarting—symptoms may reverse after discontinuation and/or hemodialysis
- If creatinine rises mid-course, pause until pharmacy recalculates—do not continue q8h by habit
- Escalate CDAD suspicion early; do not automatically restart ceftazidime if alternative therapy is needed
4. Critical teach-back questions
- “What new symptoms should you report while on this IV antibiotic?” (Confusion, twitching, severe diarrhea, rash, breathing trouble.)
- “Why might your nurse ask about kidney function before each dose?” (Ceftazidime is cleared by the kidneys; dose must change when kidney function falls.)
5. Care coordination
Pharmacist: Renal dose verification, HD/CAPD scheduling, Y-site compatibility, and alternative agents if neurotoxicity occurs
Prescriber / nephrology: Notify for rising creatinine, dialysis timing questions, or need to switch antibiotic class after serious reaction
🧠 Quick mental checklist
- What is this patient’s current CrCl and does the MAR interval match Table 4?
- Has creatinine changed since the order was written?
- Any new confusion, myoclonus, or speech change since the last dose?
- Are vancomycin or aminoglycosides scheduled in the same bag or line without pharmacy clearance?
- If neurotoxicity suspected, is ceftazidime held and prescriber/pharmacy notified?
Ceftazidime NCLEX practice questions
Practice NCLEX-style clinical judgment practice for ceftazidime using a tabbed inpatient case (MAR, labs, I&O, nursing notes), then priority action, cue recognition, trend interpretation, matrix urgency sorting, renal dosing judgment, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Ceftazidime 2 g IV q8h — given 0600, 1400; 2200 due
- Vancomycin IV (separate line) per pharmacy — trough pending
- Furosemide 40 mg IV daily — 0800 given
- Pharmacy renal note on chart: GFR 26 mL/min — q8h schedule not adjusted on MAR (Table 4 requires 1 g q24h)
- Admission CrCl ≈ 48 mL/min; today creatinine 2.6 mg/dL (was 1.9), estimated CrCl 26 mL/min
- BMP: K 4.8 mEq/L; BUN 48 mg/dL
- Blood cultures: gram-negative rods in 1/2 bottles (preliminary)
- Previous 24 h: intake 1.8 L; output 650 mL (≈27 mL/h average)
- Weight up 1.4 kg; mild dependent edema; patient reports dry mouth
- 0800–1600: output 120 mL despite diuretic
- 1545: 82-year-old with Pseudomonas ventilator-associated pneumonia; intermittent confusion overnight attributed to “ICU delirium”
- 1630: New bilateral hand myoclonus during conversation; oriented only to person
- 1640: Nurse reviewing MAR, labs, and I&O before 2200 ceftazidime dose
Answer key & rationale
Frequently asked questions
When must nurses adjust ceftazidime for renal function?
Tazicef prescribing information recommends reducing the dose when glomerular filtration rate is less than 50 mL/min—for example, GFR 50–31 mL/min uses 1 g every 12 hours; GFR 30–16 mL/min uses 1 g every 24 hours. Recalculate after acute kidney injury, dehydration, or dialysis changes. Verify pharmacy-adjusted orders before each dose.
What neurotoxicity signs should make a nurse hold ceftazidime?
Hold and escalate for seizures, encephalopathy, coma, asterixis, neuromuscular excitability, or myoclonia—especially when renal function is impaired and dosing was not adjusted. Discontinue ceftazidime per prescriber direction; hemodialysis or peritoneal dialysis may aid removal in renal failure.
How should ceftazidime be given IV?
For direct intermittent IV use, inject ceftazidime slowly over 3 to 5 minutes or infuse in compatible fluid per Tazicef labeling. Do not add ceftazidime to the same solution as aminoglycosides. Administer vancomycin separately because physical incompatibility can occur. Avoid intra-arterial injection.
Is ceftazidime safe in penicillin-allergic patients?
Ceftazidime is contraindicated in patients with hypersensitivity to ceftazidime or cephalosporins. Cross-hypersensitivity among beta-lactams may occur in up to 10% of patients with penicillin allergy history. Obtain allergy history before the first dose and stop the infusion if an allergic reaction occurs.
What is the antidote for ceftazidime overdose?
No specific antidote is listed in the reviewed prescribing information. Overdose management is careful observation and supportive treatment. In renal insufficiency, hemodialysis or peritoneal dialysis may aid removal. Contact local poison control or toxicology services per facility protocol.
References
-
U.S. National Library of Medicine. Tazicef (ceftazidime for injection, USP) — Full prescribing information. DailyMed (Hospira, Inc.).https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40d48c5d-650e-461b-a67b-7e65772d1b92
-
Drugs and Lactation Database (LactMed). Ceftazidime. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/n/lactmed/ceftazidime/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.